Date: 2016-05-18
Type of information: Nomination
Compound:
Company: Vaximm (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 18, 2016, Vaximm announced the appointment of Dr. Jarl Ulf Jungnelius to the newly created position of Chief Medical Officer. Dr. Jungnelius is a seasoned healthcare professional, having spent over thirty years practicing medicine and leading key drug development projects for international pharmaceutical companies, with a strong focus on oncology. He worked for nearly eight years at Celgene, most recently as Vice President Oncology, Global Solid Tumor Development TA Head, where he was responsible for clinical research and development of a number of programs, including for the cancer drugs, Abraxane®, Revlimid® and Vidaza®. While at Celgene, he was also involved in the company’s immuno-oncology business development efforts.
- Prior to this he was at Pfizer, where he worked on a number of projects, serving as Executive Director, Full Development Team Leader, Oncology Clinical Development, Global Research and Development, responsible for several late-stage and early development programs, including immune therapeutics. Before that, he spent almost ten years at Eli Lilly, rising to Arzoxifene Product Team Director and Chair of Lilly’s Breast Strategy Team. While at Lilly, he was a key member of the team responsible for gaining multiple marketing approvals of Gemzar®, a widely used chemotherapy and one of the few drugs approved to treat pancreatic cancer.
- In his various roles, Dr. Jungnelius’ responsibilities also included extensive interaction with regulatory authorities on a number of oncology programs. Prior to joining the pharmaceutical industry, he worked as a clinical oncologist in the department of Oncology at the Karolinska Hospital in Stockholm, Sweden. Dr. Jungnelius received his undergraduate and medical degrees from the Karolinska Institute in Sweden and is a Board-certified oncologist. He has served on the Board of a number of companies, including Biovica, Isofol Medical, Monocl and Oncopeptides.
Financial terms:
Latest news:
Is general: Yes
